Abstract:Bone metastases are common in patients with many types of cancer, especially breast and prostate cancer--in which the incidence is approximately 70% among patients with advanced metastatic disease. Aminobisphosphonates (NBPs) have entered clinical practice in the treatment of bone metastases from several neoplasms, including breast and prostate adenocarcinoma, as a result of their anti-resorption properties. However, evidence has accumulated on the direct anti-tumour effects of NBPs. This review describes the metabolic pathways that are putative molecular targets of NBPs and that are involved in the prenylation processes of several intracellular small GTP-binding proteins (ras family related proteins). The latter regulate the intracellular survival and proliferative pathways of tumour cells and could be the intracellular molecular targets of the NBPs responsible for the direct anti-cancer effects, even if definitive conclusions cannot be drawn at present. Different mechanisms have been reported to account for the anti-neoplastic action of NBPs, including: the induction of apoptosis; cell cycle perturbations; and anti-invasive, anti-migration and anti-angiogenic effects. Moreover, this review describes the most important clinical studies that demonstrate the activity of NBPs in preventing skeletal-related events induced by bone metastases. The main pharmacokinetic pitfalls of NBPs are described, and methods of overcoming these pitfalls through the use of liposome vehicles are proposed. Finally, the principal pre-clinical studies on the interaction between NBPs and other biological agents are also described; these studies may enable reductions in the in vivo NBP concentrations required to achieve anti-tumour activity. To date, however, the real molecular targets of NBPs are not completely known and new technological platforms are required in order to detect them and to develop new anti-cancer strategies based on the use of NBPs.

Activity of Nitrogen-Containing and Non-Nitrogen-containing Bisphosphonates on Tumor Cell Lines.

Activity of Sulfonium Bisphosphonates on Tumor Cell Lines.

Bifunctional Platinum(II) Complexes with Bisphosphonates Substituted Diamine Derivatives: Synthesis and in Vitro Cytotoxicity

Synthesis and cytotoxicity of O,O'-dialkyl {[2-(substituted phenoxy)acetamido](substituted phenyl)methyl}phosphonates.

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Biological effects of aromatic bis[aminomethylidenebis(phosphonic)] acids in osteoclast precursors in vitro

Solid-state NMR, Crystallographic, and Computational Investigation of Bisphosphonates and Farnesyl Diphosphate Synthase-Bisphosphonate Complexes.

Platinum(II) Compounds Bearing Bone-Targeting Group: Synthesis, Crystal Structure and Antitumor Activity.

Synthesis and Screening of Novel Inositol Phosphonate Derivatives for Anticancer Functions in Vitro

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.

Synthesis and Structure-Activity Relationships Study of Α -Aminophosphonate Derivatives Containing a Quinoline Moiety

A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors

Cytotoxicity of Synthesized 1,4-Naphthoquinone Oxime Derivatives on Selected Human Cancer Cell Lines.

Synthesis and Evaluation of a Novel Series of Diphenylamine and Diphenylether Derivatives with Osteoblastogenic and Osteogenic Effects via CDK8 Inhibition

Emerging anti-cancer molecular mechanisms of aminobisphosphonates

Preliminary Study on Alendronate Inhibiting Two Oral Squamous Carcinoma Cell Lines

Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Synthesis And Anti-Tumor Study Of 3-Aryl-4-Oxo-Thiazolidin-2-Carboxylic Acid Amides

Using Molecular Dynamics to Model the Binding Affinities of Nitrogen-Containing Bisphosphonates on Hydroxyapatite Surface

Synthesis and Antitumor Activity of Α-Aminophosphonate Derivatives Containing Thieno[2,3-D]pyrimidines

Uncovering the Potential of O-Prenylated 3-aryl-benzopyran Derivatives as Osteogenic and Cancer Cell Growth Inhibitory Agents